← Leaderboards
Katie Reindl
North Dakota State University
$1,448,858
Attributed
$1,638,216
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $433.9K · FY2015–20$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$1,638,216 · 3
By mechanism
P20$825,565 · 1
R15$433,934 · 1
R21$378,717 · 1
Top collaborators
- Melpo Christofidou-Solomidou2 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsBaseCancer CellResistanceEffective TherapyReactive Oxygen SpeciesCancer TherapyNeoplastic CellLiteratureCellsMolecularMouse ModelDietCell TypeMissionPropertyFruitRadiation TherapyDna DamageEffectivenessNovel StrategiesCapsicumCell Death
Grant awards (7)
GSTP1 as a therapeutic target for pancreatic cancer$433,934
R15 · FY2020 · CA · contact PI
Combination Therapy: Targeting Pancreatic Cancer with a ROS Inducer and Gemcitabine$202,991
P20 · FY2019 · GM · contact PI
Combination Therapy: Targeting Pancreatic Cancer with a ROS Inducer and Gemcitabine$192,268
P20 · FY2018 · GM · contact PI
Combination Therapy: Targeting Pancreatic Cancer with a ROS Inducer and Gemcitabine$212,806
P20 · FY2017 · GM · contact PI
Combination Therapy: Targeting Pancreatic Cancer with a ROS Inducer and Gemcitabine$217,500
P20 · FY2016 · GM · contact PI
Piperlongumine as a Novel Radiosensitizer for Lung Cancer$167,149
R21 · FY2016 · CA · contact PI
Piperlongumine as a Novel Radiosensitizer for Lung Cancer$211,568
R21 · FY2015 · CA · contact PI